SEC Tracker
Get the app

Longeveron LGVN

Longeveron announces ELPIS II trial results

Item 8.01 Other events

Form
8-K
Filed
Importance
Routine
  1. ELPIS II trial did not meet primary endpoint
  2. laromestrocel showed fewer clinical events than standard of care
  3. MACE showed statistical significance (P=0.043)

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Longeveron files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Lipocine LPCN public float $16M, Jun 30, 2025
  2. Marker Therapeutics MRKR public float $17M, Jun 30, 2025
  3. CalciMedica CALC public float $16M, Jun 30, 2025
  4. Ernexa Therapeutics ERNA public float $18M, Jun 30, 2025
  5. Charlie's Holdings CHUC public float $18M, Jun 30, 2025